Totolici, S.; Vrabie, A.-M.; Badila, E.; Weiss, E. Onco-Hypertension: A Continuously Developing Field between Cancer and Hypertension. Int. J. Mol. Sci.2024, 25, 3442.
Totolici, S.; Vrabie, A.-M.; Badila, E.; Weiss, E. Onco-Hypertension: A Continuously Developing Field between Cancer and Hypertension. Int. J. Mol. Sci. 2024, 25, 3442.
Totolici, S.; Vrabie, A.-M.; Badila, E.; Weiss, E. Onco-Hypertension: A Continuously Developing Field between Cancer and Hypertension. Int. J. Mol. Sci.2024, 25, 3442.
Totolici, S.; Vrabie, A.-M.; Badila, E.; Weiss, E. Onco-Hypertension: A Continuously Developing Field between Cancer and Hypertension. Int. J. Mol. Sci. 2024, 25, 3442.
Abstract
The prognosis of cancer patients has greatly improved in the last years, owing to the development of novel chemotherapeutic agents. However, this progress comes with an increasing occurrence of cardiovascular adverse reactions. A serious side effect is arterial hypertension, which is the most frequent comorbidity encountered in cancer patients, influencing the outcomes in cancer survivors. Even though secondary hypertension related to specific chemotherapeutic agents, such as vascular endothelial growth factor inhibitors, is usually mild and reversible, in rare instances it can be severe, leading to discontinuation of chemotherapy. In addition, hypertension per se has been studied as a potential risk factor for cancer development. The relationship is even more complex than previously thought, as concerning evidence recently highlighted the potential oncogenic effects of antihypertensive drugs, such as thiazide diuretics predisposing to skin cancer. As a result, under the light of the similar risk factors and overlapping pathophysiological mechanisms between hypertension and cancer, a promising concept of onco-hypertension has emerged, aiming to improve the understanding of the complicated interplay between these two pathologies and maintain a balance between the efficacy and risks of both antihypertensive drugs and chemotherapy agents.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
